Multidrug resistance: An emerging crisis

Interdisciplinary Perspectives on Infectious Diseases

Volumn 2014, Issue , 2014, Pages

  Tanwar, Jyoti ^a   Das, Shrayanee ^a   Fatima, Zeeshan ^a   Hameed, Saif ^a  

^a AMITY UNIVERSITY HARYANA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM; DEATH; FOOD HANDLING; FUNGUS; HEALTH CARE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; HYGIENE; INFECTION CONTROL; INFECTION PREVENTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PARASITE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIRUS;

EID: 84925862336     PISSN: 1687708X     EISSN: 16877098     Source Type: Journal    
DOI: 10.1155/2014/541340     Document Type: Review

References (49)

1. V. Singh, "Antimicrobial resistance, " in Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education, vol. 1, pp. 291-296, Formatex Research Center, 2013.
2. M. Popęda, E. Płuciennik, and A. K. Bednarek, "Proteins in cancer resistance, " Postępy Higieny i Medycyny Dos̈wiadczalnej, vol. 68, pp. 616-632, 2014.
3. H. Nikaido, "Multidrug resistance in bacteria, " Annual Review of Biochemistry, vol. 78, pp. 119-146, 2009.
4. Antimicrobial Resistance Global Report on Surveillance, World Health Organization, Geneva, Switzerland, 2014.
5. J. Loeffler and D. A. Stevens, "Antifungal drug resistance, " Clinical Infectious Diseases, vol. 36, no. 1, pp. S31-S41, 2003.
6. L. Strasfeld and S.Chou, "Antiviral drug resistance: mechanisms and clinical implications, " Infectious Disease Clinics of North America, vol. 24, no. 2, pp. 413-437, 2010.
7. S. Margeridon-Thermet and R. W. Shafer, "Comparison of the mechanisms of drug resistance among HIV, hepatitis B, and hepatitis C, " Viruses, vol. 2, no. 12, pp. 2696-2739, 2010.
8. B. Ullman, "Multidrug resistance and P-glycoproteins in parasitic protozoa, " Journal of Bioenergetics and Biomembranes, vol. 27, no. 1, pp. 77-84, 1995.
9. R. M. Greenberg, "New approaches for understanding mechanisms of drug resistance in schistosomes, " Parasitology, vol. 140, no. 12, pp. 1534-1546, 2013.
10. D. C. McFadden, S. Tomavo, E. A. Berry, and J. C. Boothroyd, "Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquoneresistance, " Molecular and Biochemical Parasitology, vol. 108, no. 1, pp. 1-12, 2000.
11. K. Nagamune, S. N. J. Moreno, and L. D. Sibley, "Artemisininresistant mutants of Toxoplasma gondii have altered calcium homeostasis, " Antimicrobial Agents and Chemotherapy, vol. 51, no. 11, pp. 3816-3823, 2007.
12. C. Doliwa, S. Escotte-Binet, D. Aubert et al., "Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters, " Parasite, vol. 20, no. 19, pp. 1-6, 2013.
13. M. Vanaerschot, F. Dumetz, S. Roy, A. Ponte-Sucre, J. Arevalo, and J. C. Dujardin, "Treatment failure in leishmaniasis: drugresistance or another (epi-) phenotype?" Expert Review of Anti-InfectiveTherapy, vol. 12, no. 8, pp. 937-946, 2014.
14. S. Mohapatra, "Drug resistance in leishmaniasis: newer developments, " Tropical Parasitology, vol. 4, no. 1, pp. 4-9, 2014.
15. Z. Yang, C. Li, M. Miao et al., "Multidrug-resistant genotypes of plasmodium falciparum, Myanmar, " Emerging Infectious Diseases, vol. 17, no. 3, pp. 498-501, 2011.
16. D. Bansal, R. Sehgal, Y. Chawla, N. Malla, and R. C.Mahajan, "Multidrug resistance in amoebiasis patients, " Indian Journal of Medical Research, vol. 124, no. 2, pp. 189-194, 2006.
17. L.Rodero, E.Mellado, A. C. Rodriguez et al., "G484Saminoacid substitution in lanosterol 14-α demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate, "AntimicrobialAgents and Chemotherapy, vol. 47, no. 11, pp. 3653-3656, 2003.
18. S. J. Howard and M. C. Arendrup, "Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection, " Medical Mycology, vol. 49, no. 1, pp. S90-S95, 2011.
19. M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzón, and J. L. Rodriguez-Tudela, "Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents, " Antimicrobial Agents and Chemotherapy, vol. 47, no. 7, pp. 2339-2341, 2003.
20. N. S. Lurain and S. Chou, "Antiviral drug resistance of human cytomegalovirus, " Clinical Microbiology Reviews, vol. 23, no. 4, pp. 689-712, 2010.
21. P. Wutzler, "Antiviral therapy of herpes simplex and varicellazoster virus infections, " Intervirology, vol. 40, no. 5-6, pp. 343-356, 1997.
22. K. J. Cortez and F. Maldarelli, "Clinical management of HIV drug resistance, " Viruses, vol. 3, no. 4, pp. 347-378, 2011.
23. A. C. Hurt, "The epidemiology and spread of drug resistant human influenza viruses, " Current Opinion in Virology, vol. 8, pp. 22-29, 2014.
24. J. Suppiah, R. M. Zain, S. H. Nawi, N. Bahari, and Z. Saat, "Drug-resistance associated mutations in polymerase (p) gene of hepatitis B virus isolated from malaysian HBV carriers, " HepatitisMonthly, vol. 14, no. 1, Article IDe13173, 7 pages, 2014.
25. P. B. Bloland, Drug Resistance in Malaria, World Health Organization, 2001.
26. P. G. Fallon and M. J. Doenhoff, "Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific, " The American Journal of Tropical Medicine and Hygiene, vol. 51, no. 1, pp. 83-88, 1994.
27. L. Qi and J. Cui, "A schistosomiasis model with praziquantel resistance, " Discrete Dynamics in Nature and Society, vol. 2013, Article ID 945767, 13 pages, 2013.
28. D. Bansal, N. Malla, and R. C. Mahajan, "Drug resistance in amoebiasis, " Indian Journal of Medical Research, vol. 123, no. 2, pp. 115-118, 2006.
29. C. A. Muzny and J. R. Schwebke, "The clinical spectrum of Trichomonas vaginalis infection and challenges to management, " Sexually Transmitted Infections, vol. 89, no. 6, pp. 423-425, 2013.
30. J. W. Bennett, J. L. Robertson, D. R. Hospenthal et al., "Impact of extended spectrum beta-lactamase producing Klebsiella pneumoniae infections in severely burned patients, " Journal of the American College of Surgeons, vol. 211, no. 3, pp. 391-399, 2010.
31. G. I. Olasehinde, O. Ojurongbe, A. O. Adeyeba et al., "In vitro studies on the sensitivity pattern of Plasmodium falciparum to anti-malarial drugs and local herbal extracts, " Malaria Journal, vol. 13, article 63, 2014.
32. World Health Organization, "Antimicrobial resistance, " 2014.
33. J. Fishbain and A. Y. Peleg, "Treatment of Acinetobacter infections, " Clinical Infectious Diseases, vol. 51, no. 1, pp. 79-84, 2010.
34. S. Khalilzadeh, M. R. Boloorsaz, A. Safavi, P. Farnia, and A. A. Velayati, "Primary and acquired drug resistance in childhood tuberculosis, " EasternMediterranean Health Journal, vol. 12, no. 6, pp. 909-914, 2006.
35. C. R. Lee, I. H. Cho, B. C. Jeong, and S. H. Lee, "Strategies to minimize antibiotic resistance, " International Journal of Environmental Research and Public Health, vol. 10, no. 9, pp. 4274-4304, 2013.
36. S. M. Marks, J. Flood, B. Seaworth et al., "Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007, " Emerging Infectious Diseases, vol. 20, no. 5, pp. 812-821, 2014.
37. G. S. Chethana, K. R. Hari venkatesh, F. Mirzaei, and S. M. Gopinath, "Review on multidrug resistant bacteria and its implication in medical sciences, " Journal of Biological Scientific Opinion, vol. 1, no. 1, pp. 32-37, 2013.
38. X.He, S. Li, and S. G. Kaminskyj, "Using Aspergillus nidulans to identify antifungal drug resistance mutations, " Eukaryotic Cell, vol. 13, no. 2, pp. 288-294, 2013.
39. M. N. Alekshun and S. B. Levy, "Molecular mechanisms of antibacterialmultidrug resistance, " Cell, vol. 128, no. 6, pp. 1037-1050, 2007.
40. F. C. Tenover, "Mechanisms of antimicrobial resistance in bacteria, " The American Journal of Medicine, vol. 119, no. 6, pp. S3-S10, 2006.
41. S. Dzidic, J. Suskovic, and B. Kos, "Antibiotic resistance mechanisms in bacteria: biochemical and genetic aspects, " Food Technology and Biotechnology, vol. 46, no. 1, pp. 11-21, 2008.
42. X. Z. Li and H. Nikaido, "Efflux-mediated drug resistance in bacteria: an update, " Drugs, vol. 69, no. 12, pp. 1555-1623, 2009.
43. E. Orozco, C. López, C. Gómez et al., "Multidrug resistance in the protozoan parasite Entamoeba histolytica, " Parasitology International, vol. 51, no. 4, pp. 353-359, 2002.
44. M. Ouellette, D. Légaré, and B. Papadopoulou, "Multidrug resistance and ABC transporters in parasitic protozoa, " Journal of Molecular Microbiology and Biotechnology, vol. 3, no. 2, pp. 201-206, 2001.
45. S. Kunjachan, B. Rychlik, G. Storm, F. Kiessling, and T. Lammers, "Multidrug resistance: physiological principles and nanomedical solutions, " Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1852-1865, 2013.
46. C. P.Wu, S.Ohnuma, and S.V.Ambudkar, "Discovering natural productmodulators to overcomemultidrug resistance in cancer chemotherapy, " Current Pharmaceutical Biotechnology, vol. 12, no. 4, pp. 609-620, 2011.
47. K.W.Hamilton andN.O. Fishman, "Antimicrobial stewardship interventions: thinking inside and outside the box, " Infectious Disease Clinics ofNorthAmerica, vol. 28, no. 2, pp. 301-313, 2014.
48. R. C. Owens Jr., "Antimicrobial stewardship: concepts and strategies in the 21st century, " Diagnostic Microbiology and Infectious Disease, vol. 61, no. 1, pp. 110-128, 2008.
49. R.W.Moehring andD. J.Anderson, "Antimicrobial stewardship as part of the infection prevention effort, " Current Infectious Disease Reports, vol. 14, no. 6, pp. 592-600, 2012.